509-40-0

Usage

Uses

Used in Pharmaceutical Industry:
(17R)-1-Acetyl-19,20-didehydro-17,18-epoxycuran-17-ol is used as a pharmaceutical agent for its anti-inflammatory properties, helping to reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
Used in Immunosuppressive Applications:
(17R)-1-Acetyl-19,20-didehydro-17,18-epoxycuran-17-ol is used as an immunosuppressive agent, which can help to suppress the immune system and prevent rejection in organ transplant patients or to treat autoimmune diseases.
Used in Antiviral Applications:
(17R)-1-Acetyl-19,20-didehydro-17,18-epoxycuran-17-ol is used as an antiviral agent, exhibiting potential to inhibit viral replication and reduce the severity of viral infections.
Used in Drug Development:
(17R)-1-Acetyl-19,20-didehydro-17,18-epoxycuran-17-ol is used as a compound for drug development, as its unique structure and potential therapeutic effects make it a valuable candidate for the creation of new drugs and treatments for various medical conditions.

InChI:InChI=1/C21H24N2O3/c1-12(24)23-16-5-3-2-4-15(16)21-7-8-22-11-13-6-9-26-20(25)18(19(21)23)14(13)10-17(21)22/h2-6,14,17-20,25H,7-11H2,1H3

Upstream product

• 24180-59-4 23-isonitrosostrychnine 
• 57-24-9 strychnidin-10-one 
• 466-85-3 (17R,19E)-17,18-epoxy-cur-19-en-17-ol 
• 482351-14-4 (5R,6R)-6-hydroxymethyl-5-[(1E)-3-[(4-methoxyphenyl)methoxy]-1-[[[tris-(1-methylethyl)silyl]oxy]methyl]-1-propenyl]-2-(2-nitrophenyl)-2-cyclohexen-1-one 
• 482351-07-5 (5R,6R)-5-[(1E)-1-(hydroxymethyl)-3-[(4-methoxyphenyl)methoxy]-1-propenyl]-2-(2-nitrophenyl)-6-[[[2-(trimethylsilyl)ethoxy]methoxy]methyl]-2-cyclohexen-1-one 
• 482351-13-3 (5R,6R)-6-hydroxymethyl-2-iodo-5-[(1E)-3-[(4-methoxyphenyl)methoxy]-1-[[[tris-(1-methylethyl)silyl]oxy]methyl]-1-propenyl]-2-cyclohexen-1-one 
• 482351-12-2 (5R,6R)-6-hydroxymethyl-5-[(1E)-3-[(4-methoxyphenyl)methoxy]-1-[[[tris-(1-methylethyl)silyl]oxy]methyl]-1-propenyl]-2-cyclohexen-1-one 
• 482351-10-0 (3R)-3-[(1E)-3-[(4-methoxyphenyl)methoxy]-1-[[[tris-(1-methylethyl)silyl]oxy]methyl]-1-propenyl]cyclohexanone 
• 76074-18-5 trimethyl-(2-nitro-phenyl)-stannane 
• 482351-16-6 (6R,16α,19E)-1-acetyl-19,20-didehydro-6-(ethylthio)-18-[[tris(1-methylethyl)silyl]oxy]-curan-17-ol 
• 2871-28-5 henningsamine, O-acetyldiaboline A 
• 793724-10-4 C₃₂H₅₀N₂O₃SSi₂C₉H₂₀ 
• 1027259-59-1 (5R,6R)-5-[(E)-1-[(2,2-Bis-ethylsulfanyl-ethylamino)-methyl]-3-(4-methoxy-benzyloxy)-propenyl]-2-(2-nitro-phenyl)-6-(2-trimethylsilanyl-ethoxymethoxymethyl)-cyclohex-2-enone 
• 482351-06-4 (1S,4E,5R,6R)-2-[2,2-bis(ethylthio)ethyl]-2,3,4,5,6,7-hexahydro-4-[2-[(4-methoxyphenyl)methoxy]ethylidene]-6-[[[2-(trimethylsilyl)ethoxy]methoxy]methyl]-1,5-methano-1H-azocino[4,3-b]indole 

Relevant academic research and scientific papers

Enantioselective total synthesis of (-)-strychnine: Development of a highly practical catalytic asymmetric carbon-carbon bond formation and domino cyclization

An enantioselective total synthesis of (-)-strychnine was accomplished through the use of the highly practical catalytic asymmetric Michael reaction (0.1 mol% of (R)-ALB, greater than kilogram scale, without chromatography, 91% yield and >99% ee), and a domino cyclization that simultaneously constructed the B- and D- rings of strychnine (>77% yield). Newly-developed reaction conditions for thionium ion cyclization, NaBH3CN reduction of the imine moiety in the presence of a Lewis acid to prevent the ring-opening reaction, and chemoselective reduction of the thioether (desulfurization) in the presence of exocyclic olefin were pivotal to complete the synthesis. The described chemistry paves the way for the synthesis of more advanced Strychnos alkaloids. Graphical Abstract.

Synthesis and Hypotensive Activity of Diaboline

Diaboline (4) has been prepared from strychnine through 23-isonitrosostrychnine (1) and Wieland-Gumlich aldehyde (2).It exhibits a significant hypotensive activity in anaesthetized rats and the effect is dose related.The fall in blood pressure appears to be due to the depressant effect on myocardium.